Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02385292 · ClinicalTrials.gov registry record · NA
Multicenter Trial Evaluating Quality of Tears Produced by Nasal Neurostimulation
A NA study, sponsored by Oculeve.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT02385292: Completed NA study, sponsored by Oculeve.
NCT02385292 is a NA study that has completed, run by Oculeve. The registered enrollment target is 23 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02385292, a NA study, has completed, sponsored by Oculeve.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
The objectives of this study are: * To compare the change in levels of tear proteins and inflammatory mediators pre and post administration between the intranasal and extranasal applications * To compare the goblet cell count following application between the intranasal and extranasal applications * To compare fluorescein tear clearance with the application of the device intranasally and extranasally applications
Interventions
- DEVICE Oculeve Intranasal Lacrimal Neurostimulator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-05-31 |
| Est. Completion | 2016-03-31 |
| Phase | NA |
What the finished NCT02385292 record still lists
NCT02385292 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Oculeve Intranasal Lacrimal Neurostimulator is the first listed.
NCT02385292 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02385292 about?
NCT02385292 is a clinical study titled "Multicenter Trial Evaluating Quality of Tears Produced by Nasal Neurostimulation". The objectives of this study are: * To compare the change in levels of tear proteins and inflammatory mediators pre and post administration between the intranasal and extranasal applications * To compare the goblet cell count following application between the intranasal and extranasal applications ...
What is the current status of trial NCT02385292?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2015-05-31. Estimated completion is 2016-03-31.
What interventions are being tested in trial NCT02385292?
The interventions under investigation include: Oculeve Intranasal Lacrimal Neurostimulator (DEVICE).
Who is sponsoring clinical trial NCT02385292?
This trial is sponsored by Oculeve, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02385292's enrollment target sits among peer trials
23 1755th of 2000 higher than 245 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI